2026-06-01T02:08:52Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1162602025-01-30T10:01:55Zcom_20.500.14352_14col_20.500.14352_15

Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants García Pérez, Javier Portolés Pérez, Antonio Pérez Ingidua, Carla Lora Pablos, David Gómez De La Cámara, Agustín Ramón Díez Fuertes, Francisco Ascaso del Río, Ana 612.017 614.2 Inmunología Farmacología (Medicina) Enfermedades infecciosas 3202 Epidemiología 3212 Salud Publica 3209 Farmacología 2412 Inmunología Summary CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months. The third vaccine dose of mRNA-1273 in naive participants previously vaccinated with ChAdOx1-S/BNT162b2 regimen reached higher neutralizing antibodies titers against the variants of concern Delta and BA.1 lineage of Omicron compared with those receiving a third dose of BNT162b2 at day 28. These differences between BNT162b2 and mRNA-1273 arms were observed against the ancestral variant G614 at day 90. Suboptimal neutralizing response was observed against BQ.1.1, XBB.1.5/XBB.1.9, and JN.1 in a relevant proportion of individuals 180 days after the third dose, even after asymptomatic Omicron breakthrough infections. EudraCT (2021-001978-37); ClinicalTrials.gov (NCT04860739). Instituto de Salud Carlos III (España) Depto. de Enfermería Depto. de Farmacología y Toxicología Fac. de Enfermería, Fisioterapia y Podología Fac. de Medicina Fac. de Estudios Estadísticos TRUE pub 2025-01-27T11:51:34Z 2025-01-27T11:51:34Z 2024-09-20 journal article VoR https://hdl.handle.net/20.500.14352/116260 2589-0042 10.1016/j.isci.2024.110728 eng García-Pérez J, Borobia AM, Pérez-Olmeda M, Portoles A, Castaño L, Campins-Artí M, Bertrán MJ, Bermejo M, Arribas JM, López A, Ascaso-del-Rio A, Arana-Arri E, Fuentes Camps I, Vilella A, Cascajero A, García-Morales MT, Castillo de la Osa M, Pérez Ingidua C, Lora D, Jiménez-Santana P, Pino-Rosa S, Gómez de la Cámara A, De La Torre-Tarazona E, Calonge E, Cruces R, Belda-Iniesta C, Alcamí J, Frías J Carcas AJ, Díez-Fuertes F, * and CombiVacS Study Group. Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants. iScience. 2024 Sep; 27;9:110728. ISSN 2589-0042. https://doi.org/10.1016/j.isci.2024.110728. Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ open access application/pdf Elsevier